New Treatment Strategies in Metastatic Lung Cancer

Description:

Even the most skeptical among us would agree that we have made progress in the treatment of metastatic Non-Small-Cell Lung Cancer (NSCLC) over the past decade. The early 1990s witnessed the arrival of kinder and gentler chemotherapy regimens ably supported by very effective anti-nausea medications resulting in modest improvement in the outcomes. The introduction of novel molecular targeted agents, led initially by gefitinib and followed now by several other agents inhibiting different pathways, has opened a new avenue for therapy and hope. Targeted therapy is now a reality not only for patients with advanced Non-Small-Cell Lung Cancer progressing after chemotherapy but also in the front-line setting (for a select group of patients) with bevacizumab, an inhibitor of anti-angiogenic therapy. With all these new developments (and more), the treatment of advanced Non-Small-Cell Lung Cancer is now quite challenging and constantly changing. It is my distinct pleasure and privilege to present you an up-to-date monograph on the contemporary (2008) management of metastatic Non-Small-Cell Lung Cancer. This monograph, as with our other monographs in this series, is intended to guide the practicing oncologists in the community. The practical advice that you will get from this panel of experts flows not only from a wealth of research experience, but is also seasoned very well by years of clinical experience. Apart from covering the management of advanced Non-Small-Cell Lung Cancer in the first- and second-line setting and beyond with cytotoxic chemotherapy and molecular targeted therapy, we have included two interesting sections, one on the management of the ubiquitous rash secondary to epidermal growth factor receptor therapy and another on the “curative” options for metastatic Non-Small-Cell Lung Cancer. The two words curative and metastatic may not have gone into one sentence regarding Non-Small-Cell Lung Cancer 10 years ago, but we are now emboldened to think about this possibility, even though only for a rare patient. That is definitely a sign of changing times.

Click Download below and Your Download will start on new tab.
Please click ads to keep this service free.
Download